Download PDF
CC BY-NC-ND 4.0 · The Arab Journal of Interventional Radiology 2018; 2(02): 75-81
DOI: 10.4103/AJIR.AJIR_11_18
Original Article

Outcome of Transjugular Intrahepatic Portosystemic Shunt in Budd-Chiari Syndrome: Long-Term Outcomes of 118 Patients; A Single-center Experience

Mohamed Shaker
Departments of Radiodiagnosis and Interventional Radiology, Ain Shams University, Cairo, Egypt
,
Mohammad Sakr
Department of Tropical Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
,
Hany Dabbous
Department of Tropical Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
,
Sara M. Abdelhakam
Department of Tropical Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
,
Ahmed Samir
Department of Tropical Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
,
Hend Ebada
Department of Tropical Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
,
Amir M. Farid
Department of Tropical Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
,
Mohamed El-Gharib
Departments of Radiodiagnosis and Interventional Radiology, Ain Shams University, Cairo, Egypt
,
Ahmed Eldorry
Departments of Radiodiagnosis and Interventional Radiology, Ain Shams University, Cairo, Egypt
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints

Context: Budd–Chiari syndrome (BCS) is a heterogeneous group of clinical conditions ranging from acute liver failure to completely asymptomatic patient. Patients with BCS nonresponsive to medical treatment or who are not candidates for angioplasty/stenting are routinely treated with transjugular intrahepatic portosystemic shunt (TIPS) to improve portal venous outflow. Aims: This retrospective study aims at determining the short and long-term outcomes of TIPS in BCS patients. Subjects and Methods: This retrospective study included 118 patients with primary BCS who underwent TIPS from 2005 to 2011. They were classified according to Child-Pugh, model for end-stage liver disease (MELD), Rotterdam and BCS-TIPS scores. Short-term outcome of TIPS (<1 year) was determined and included immediate postprocedure complications, effect on clinical status, liver profile, and stent patency. Long-term outcome (1–5 years) was determined and included stent patency rate, time, and pattern of management of stent occlusion and survival rates at 1, 3, and 5 years. Statistical Analysis Used: SPSS statistical package version 16. Paired t-test was used to compare pre and post-TIPS MELD and Child-Pugh scores. Chi-square test and Kaplan–Meier survival curve were used to examine the association between short- and long-term occlusion, liver function and survival outcomes. P < 0.05 was considered statistically significant. Results: By the 1st year, there was a significant decline in the percentage of patients having ascites and abdominal pain, increase in mean serum albumin from 3.42–4.02 g/dl and reduction in bilirubin levels from 2.57–1.35 mg/dl (P < 0.001). The rate of stent occlusion by the 1st year was 27.4%. During long-term follow-up, there was a marked improvement in clinical status, liver profile, Child–Pugh, and MELD scores (P < 0.001). The 1- and 5-year shunt patency rates were 72.6% and 78.7%, respectively. The main management of post-TIPS occlusion was angioplasty without stenting. The 1-, 3-, and 5-year survival rates were 95.8%, 93.2%, and 91.5%, respectively. There was a significant relation between survival and post-TIPS MELD score (P = 0.009). Conclusions: TIPS is an effective treatment modality for BCS and has a long-term survival benefit with satisfactory shunt patency and patient survival.

Budd–Chiari syndrome - outcome - stent occlusion - survival - transjugular intrahepatic portosystemic shunt


Publication History

Article published online:
10 April 2021

© 2018. The Arab Journal of Interventional Radiology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 DeLeve LD, Valla DC, Garcia-Tsao G; American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology 2009;49:1729-64.
  • 2 Martens P, Nevens F. Budd-Chiari syndrome. United European Gastroenterol J 2015;3:489-500.
  • 3 Darwish Murad S, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med 2009;151:167-75.
  • 4 Hadengue A, Poliquin M, Vilgrain V, Belghiti J, Degott C, Erlinger S, et al. The changing scene of hepatic vein thrombosis: Recognition of asymptomatic cases. Gastroenterology 1994;106:1042-7.
  • 5 Millener P, Grant EG, Rose S, Duerinckx A, Schiller VL, Tessler FN, et al. Color Doppler imaging findings in patients with Budd-Chiari syndrome: Correlation with venographic findings. AJR Am J Roentgenol 1993;161:307-12.
  • 6 de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the baveno VI consensus workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63:743-52.
  • 7 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL clinical practice guidelines: Vascular diseases of the liver. J Hepatol 2016;64:179-202.
  • 8 Fitsiori K, Tsitskari M, Kelekis A, Filippiadis D, Triantafyllou K, Brountzos E, et al. Transjugular intrahepatic portosystemic shunt for the treatment of Budd-Chiari syndrome patients: Results from a single center. Cardiovasc Intervent Radiol 2014;37:691-7.
  • 9 Cura M, Haskal Z, Lopera J. Diagnostic and interventional radiology for Budd-Chiari syndrome. Radiographics 2009;29:669-81.
  • 10 Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
  • 11 Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-6.
  • 12 Darwish Murad S, Valla DC, de Groen PC, Zeitoun G, Hopmans JA, Haagsma EB, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004;39:500-8.
  • 13 Garcia-Pagán JC, Heydtmann M, Raffa S, Plessier A, Murad S, Fabris F, et al. TIPS for Budd-Chiari syndrome: Long-term results and prognostics factors in 124 patients. Gastroenterology 2008;135:808-15.
  • 14 Madura JA, Rookstool M, Wease G. The management of patients on chronic Coumadin therapy undergoing subsequent surgical procedures. Am Surg 1994;60:542-6.
  • 15 Ryan JM, Ryan BM, Smith TP. Antibiotic prophylaxis in interventional radiology. J Vasc Interv Radiol 2004;15:547-56.
  • 16 Tripathi D, Macnicholas R, Kothari C, Sunderraj L, Al-Hilou H, Rangarajan B, et al. Good clinical outcomes following transjugular intrahepatic portosystemic stent-shunts in Budd-Chiari syndrome. Aliment Pharmacol Ther 2014;39:864-72.
  • 17 Peynircioglu B, Shorbagi AI, Balli O, Cil B, Balkanci F, Bayraktar Y, et al. Is there an alternative to TIPS? Ultrasound-guided direct intrahepatic portosystemic shunt placement in Budd-Chiari syndrome. Saudi J Gastroenterol 2010;16:315-8.
  • 18 Beddy P, Ryan JM. Antibiotic prophylaxis in interventional radiology – Anything new? Tech Vasc Interv Radiol 2006;9:69-76.
  • 19 Terreni N, Vangeli M, Raimondo ML, Tibballs JM, Patch D, Burroughs AK, et al. Late intrahepatic hematoma complicating transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome. Cardiovasc Intervent Radiol 2007;30:1065-9.
  • 20 Tripathi D, Sunderraj L, Vemala V, Mehrzad H, Zia Z, Mangat K, et al. Long-term outcomes following percutaneous hepatic vein recanalization for Budd-Chiari syndrome. Liver Int 2017;37:111-20.
  • 21 Aydinli M, Bayraktar Y. Budd-Chiari syndrome: Etiology, pathogenesis and diagnosis. World J Gastroenterol 2007;13:2693-6.
  • 22 Qi X, Yang M, Fan D, Han G. Transjugular intrahepatic portosystemic shunt in the treatment of Budd-Chiari syndrome: A critical review of literatures. Scand J Gastroenterol 2013;48:771-84.
  • 23 Zahn A, Gotthardt D, Weiss KH, Richter G, Schmidt J, Stremmel W, et al. Budd-Chiari syndrome: Long term success via hepatic decompression using transjugular intrahepatic porto-systemic shunt. BMC Gastroenterol 2010;10:25.
  • 24 Khuroo MS, Al-Suhabani H, Al-Sebayel M, Al Ashgar H, Dahab S, Khan MQ, et al. Budd-Chiari syndrome: Long-term effect on outcome with transjugular intrahepatic portosystemic shunt. J Gastroenterol Hepatol 2005;20:1494-502.